Enfuvirtide, an HIV-1 Fusion Inhibitor [1] (multiple letters)

New England Journal of Medicine

Volumn 349, Issue 18, 2003, Pages 1770-1771

  Carr, Andrew ^a   Jenny Avital, Elizabeth R ^b   Lalezari, Jacob P ^c   Lazzarin, Adriano ^d   Salgo, Miklos ^e  

^a ST VINCENT S HOSPITAL   (Australia)

^b JACOBI MEDICAL CENTER   (United States)

^c Quest Clinical Research   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 41; PEPTIDE FRAGMENT; VIRUS RNA;

CLINICAL TRIAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; LETTER; MAJOR CLINICAL STUDY; NONHUMAN; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ADSORPTION; BLOOD; DRUG EFFECT; GENETICS; NOTE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; ANTIBIOTIC RESISTANCE;

ADSORPTION; ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; RNA, VIRAL; TREATMENT FAILURE; DRUG RESISTANCE, VIRAL; VIRAL LOAD;

EID: 0142213729     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200310303491815     Document Type: Letter

References (0)